News

Researchers find a strong link between Alzheimer's disease and retinal thinning

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets.

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over inadequate screening and management, especially among Black and Hispanic youths.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.

The American Academy of Ophthalmology 2024 annual meeting features key lectures and award sessions, highlighting advancements in ophthalmology from leading experts across the field.

According to the company, MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation.

The Eye Care Network adds a longstanding, CME-certified to its live event programming.

Ten of the institute's ophthalmologists will present their work in more than 20 sessions with a wide range of topics

According to the company, the platform accompanies the launch of Qdata Retinitis Pigmentosa for life sciences and the development of Practice Insights for clinicians.

According to the company, the axitinib injectable suspension achieved all primary and secondary outcomes and maintained stable visual acuity and anatomical control over 9 months.

The trial is assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

The effort represents a consortium of researchers from Penn Medicine, Penn Engineering, the University of Michigan Kellogg Eye Center, St. John Eye Hospital in Jerusalem, and Gyeongsang National University College of Medicine in Korea.

Related macular dystrophies include Sorsby’s fundus dystrophy, Doyne honeycomb macular dystrophy, and autosomal dominant radial drusen.

According to the company, a $68 million Series D financing is co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC Inc. It also has secured $15 million in structured capital from Catalio Capital Management, with $10 million drawn at closing.

A team of researchers at Arizona State University has developed tools to aid in the diagnosis of myopic maculopathy.

Changes associated with Alzheimer's disease extend beyond the brain.

Lotfi Merabet, OD, PhD, MPH, discusses his role as co-chairman of a National Eye Institute initiative focused on advancing research in cerebral visual impairment (CVI). The initiative's key goals include raising awareness about CVI, establishing clear diagnostic criteria, and developing a national registry to track patients and their conditions over time. CVI, a complex condition that affects how the brain processes visual information, requires a multidisciplinary approach involving not only ophthalmologists and optometrists but also neuroscientists, educators, and rehabilitation specialists.

Coordinated by the International Agency for the Prevention of Blindness under the Love Your Eyes campaign banner, World Sight Day 2024 is putting children front and center in this year’s campaign.

Jeff Todd, president and CEO of Prevent Blindness, and Donna Fishman, Director of the National Center for Children’s Vision and Eye Health at Prevent Blindness, join David Hutton of Ophthalmology Times to discuss the report.

The investigators undertook a study in which they retrospectively evaluated the presence and amount of small HRF in the eyes of patients with different macular atrophic phenotypes.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

In a study, a team of UCLA investigators detail a deep-learning model pre-trained on 2D scans that accurately predicts disease-risk factors from 3D medical-scan modalities.

The donation will support the development of the Artificial Intelligence Innovation Center, a collaborative hub with a focus of preserving the vision of patients with various eye conditions and eliminating blindness.